



Press Release

March 2010

AlphaBeta Pharma Strengthens its Presence in the Middle-East by Acquiring a Cairo-based CRO

London, United Kingdom and Cairo, Egypt –March 2010- AlphaBeta Pharma strengthens its presence by acquiring El-Sahar CRO based in Cairo, Egypt.

EL SAHAR CRO is a medium-size company that has been operating since the year 2000 almost exclusively in the Middle-East countries and has been a significant player in introducing clinical research and drug development into this part of the world.

EL SAHAR CRO also operates a 40-bed Clinical Research Unit in Cairo with inpatient facilities and equipped with state-of-the art technology and staffed with well experienced and reputed clinicians and researchers and has the ability to conduct phase I-IV clinical trials in many therapeutic areas.

Ends



Note to Editors.

AlphaBeta Pharma is a successful start-up UK-based ethical speciality pharmaceutical company privately owned and independently managed. It also offers specialised services and consultancy to pharmaceutical and biotech companies as well as academic institutions.

AlphaBeta Pharma's focus is the development and marketing of pharmaceutical products that address significant unmet clinical needs in areas such as orphans, CNS and pain management. The company currently markets a range of products exclusively in the Middle-East, Turkey, Israel and South Africa markets in its key therapeutic areas.

AlphaBeta Pharma is active in research and development and currently collaborating with a number of companies and institutions and has products in various stages of clinical development.

www.AlphaBetaPharma.com